Overview
The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114.
Eligibility
Inclusion Criteria:
Participants are eligible to be included in the escalation module of the study only if all of the following criteria apply:
- Participant must be at least 18 years of age inclusive, at the time of signing the informed consent
- Participant has a histologically and/or cytologically confirmed diagnosis of one of the selected advanced solid tumor types
- Participant has advanced disease (ie, locally recurrent or metastatic) and had access to approved therapies
Exclusion Criteria:
Participants are excluded from the escalation module of the study if any of the following criteria apply:
- Participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study
- Participant has a history of severe allergic, anaphylactic, or other hypersensitivity reactions
- Participant has a known hypersensitivity to any components of the study medication or comparable drugs
- Active and clinically significant bacterial, fungal, or viral infection, known infections with hepatitis B, hepatitis C, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness
- Chronic underlying infection or disease that, in the view of the investigator, should preclude the participant from enrolling in the study